Expertise in
23
conditions

Dr. Thomas J. Herzog

Obstetrics and Gynecology
Uc Health Obgyn-West Chester Physicians Office South Building (West Chester Hospital)
7675 Wellness Way, 
West Chester, OH 
Accepting New Patients
Expertise in
23
conditions
Uc Health Obgyn-West Chester Physicians Office South Building (West Chester Hospital)
7675 Wellness Way, 
West Chester, OH 

Overview

Thomas Herzog is an Obstetrics and Gynecologist practicing medicine in West Chester, Ohio.

Dr. Herzog is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Hysterectomy, and Oophorectomy.

He is actively involved in clinical research, co-authoring 204 peer reviewed articles and participating in 13 clinical trials. Dr. Herzog is currently accepting new patients.

Specialties

Obstetrics and Gynecology

Licenses

Obstetrics & Gynecology in NY

Hospital Affiliations

Christ Hospital
West Chester Hospital
University Of Cincinnati Medical Center, LLC

Languages Spoken

English
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Health
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Uc Health Obgyn-West Chester Physicians Office South Building (West Chester Hospital)
7675 Wellness Way, West Chester, OH 45069

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 21, 2026
Intervention Type: Radiation, Drug, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
EPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer
EPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer
Enrollment Status: Terminated
Publish Date: June 04, 2026
Intervention Type: Drug
Study Drugs: Alpelisib, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD)
Study Phase: Phase 3
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
An Open Label Randomized Active Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer
An Open Label Randomized Active Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer
Enrollment Status: Completed
Publish Date: September 10, 2025
Intervention Type: Drug
Study Drugs: Paclitaxel, Afuresertib
Study Phase: Phase 2
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Enrollment Status: Completed
Publish Date: May 23, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Cisplatin
Study Phase: Phase 3
Standard Chemotherapy Versus Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
Standard Chemotherapy Versus Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 22, 2024
Intervention Type: Diagnostic test, Drug
Study Drug: Standard Chemotherapy
Study Phase: Phase 3
ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Study Drugs: Chemotherapy, Rucaparib
Study Phase: Phase 3
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Enrollment Status: Terminated
Publish Date: March 14, 2023
Intervention Type: Drug
Study Drug: ADXS11-001 L. monocytogenes Vaccine
Study Phase: Phase 3
View 9 Less Clinical Trials

204 Total Publications

Endometrial Cancer by ERBB2 Amplification (ERBB2amp) Status: Differences in Molecular Subtypes, Ancestry, and Real-World Outcomes.
Endometrial Cancer by ERBB2 Amplification (ERBB2amp) Status: Differences in Molecular Subtypes, Ancestry, and Real-World Outcomes.
Journal: JCO precision oncology
Published: July 10, 2026
Similar Doctors
Expertise in
16
conditions
Dr. Christine M. Pennesi
Obstetrics and Gynecology
Expertise in
16
conditions
Dr. Christine M. Pennesi
Obstetrics and Gynecology
Referral may be required

Cincinnati Children's Hospital Medical Center

3333 Burnet Ave, 
Cincinnati, OH 
 (16.6 miles away)
513-636-9400
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Christine Pennesi is an Obstetrics and Gynecologist practicing medicine in Cincinnati, Ohio. Dr. Pennesi is highly rated in 16 conditions, according to our data. Her clinical expertise encompasses Kuster Syndrome, Mayer-Rokitansky-Kuster-Hauser Syndrome, Mullerian Aplasia, Intrauterine Device Insertion, and Oophorectomy. Dr. Pennesi is currently accepting new patients.

Expertise in
11
conditions
Dr. Mickey M. Karram
Obstetrics and Gynecology
Expertise in
11
conditions
Dr. Mickey M. Karram
Obstetrics and Gynecology
Referral may be required

The Christ Hospital Physicians-Urogynecology

7450 S Mason Montgomery Rd Unit 201, 
Mason, OH 
 (3.0 miles away)
513-463-2500
Languages Spoken:
English, Arabic, Arabic - Jordanian, Spanish
See accepted insurances
Accepting New Patients

Mickey Karram is an Obstetrics and Gynecologist practicing medicine in Mason, Ohio. Dr. Karram is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Urinary Incontinence, Stress Urinary Incontinence, Uterine Prolapse, Bladder Reconstruction, and Reconstructive Urology Surgery. Dr. Karram is currently accepting new patients.

Expertise in
7
conditions
Dr. Rachel N. Pauls
Obstetrics and Gynecology
Expertise in
7
conditions
Dr. Rachel N. Pauls
Obstetrics and Gynecology
Referral may be required
Before you request

TriHealth Women's Services - Cincinnati Urogynecology Associates - Liberty

8020 Liberty Way, 
Liberty Township, OH 
 (0.9 miles away)
513-463-4300
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Rachel Pauls is an Obstetrics and Gynecologist practicing medicine in Liberty Township, Ohio. Dr. Pauls is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Pelvic Floor Dysfunction, Interstitial Cystitis, Uterine Prolapse, Hysterectomy, and Oophorectomy. Dr. Pauls is board certified in American Board Of Obstetrics And Gynecology - 2006 and American Board Of Obstetrics And Gynecology, Female Pelvic Medicine And Reconstructive Surgery - 2013. Dr. Pauls is currently accepting new patients.

Frequently Asked Questions about Dr. Thomas J. Herzog

How do I make an appointment with Dr. Thomas J. Herzog?

You can book an appointment with Dr. Thomas J. Herzog by calling their office at 513-475-8588. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Thomas J. Herzog a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Thomas J. Herzog is classified as an Elite expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Thomas J. Herzog specialize in?

While Dr. Thomas J. Herzog is a Obstetrics and Gynecology, they have specific expertise in Ovarian Cancer, Endometrial Cancer, and Ovarian Carcinosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Obstetrics and Gynecology.

Does Dr. Thomas J. Herzog participate in research or clinical trials?

Yes. Dr. Thomas J. Herzog has published 204 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Dr. Thomas J. Herzog's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Thomas J. Herzog accept my insurance?

Dr. Thomas J. Herzog accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 513-475-8588 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Herzog's expertise for a condition
ConditionClose
View All 15 Advanced Conditions
View All 35 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile